Developing therapeutic agents for the treatment of cancer based on the invention of Dr Shisong Jiang – Recombinant Overlapping Peptides (ROP)


The immune system employs specialised agents to attack particular targets on invading organisms and tumours. These can be either antibodies or a type of T Cells (often called cytotoxic T Lymphocytes or CTL). These CTLs are produced when a T Cell encounters a protein or other molecule it considers to be foreign and not normally found in the body. The T Cell that recognises these foreign agents is then multiplied to provide a defence against the invading organism or tumour.

Recombinant Overlapping Peptide

Tumours can often avoid being targeted by these T Cells by looking like a cell found normally in the body often referred to as “self”. If a group of T Cells can be encouraged to recognise these tumours as foreign and not self then they will attack the tumour and provide an effective treatment against it.

Injecting a preparation that stimulates these T Cells effectively vaccinates the patient against the tumour providing immediate treatment and longer term protections against it. The Oxford Vacmedix technology – the Recombinant Overlapping Peptides – is a powerful preparation that delivers just this result rolex cellini rolex calibre 9015 mingzhu engine mens m50525 0009 black.

Overlapping peptides have been found to be very effective in providing treatment for cervical cancer in early work (Ref Kenter et al.,New England Journal of Medicine, 2009, 361: 1838 – 1847). These materials had to be produced synthetically making them both expensive and hard to produce consistently. The patented Recombinant Overlapping approach produces a much more effective which is both simpler and more economical to produce.

The ROP technology platform has wide applications in cancer and infectious  diseases. New ROP vaccines are easy to design and fast to synthesize.  

Compared with conventional vaccines the ROP technology shows:  

  • much greater efficacy as it is applicable all HLA types and stimulates CD8 as well as CD4 T-cells
  • a much greater immunogenic effect and
  • the potential for synergy with other immune oncology agents, to enhance and extend the duration of effect.

The recombinant approach also has low manufacturing costs and simple regulatory pathways.

T Cell Receptor

In the image below the Recombinant Overlapping Peptide is the “Antigen” being presented to the T Cell Receptor (TCR). This then triggers the growth of T Cells that will recognise the same marker on cancer cells leading to their destruction vaporesso zero.

Image courtesy of BioPharma Dealmakers, September 2017​

Contact us

If you want to have a quick chat, or leave us some feedback,
you can contact us using any of the methods below